BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:05 ET
|
BioAtla, Inc.
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as...
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
May 23, 2024 17:04 ET
|
Cullinan Therapeutics, Inc.
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as...
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
May 23, 2024 17:03 ET
|
Regeneron Pharmaceuticals, Inc.
Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically...
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
May 23, 2024 17:01 ET
|
ZENTALIS PHARMACEUTICALS
Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared to historical comparators Results support...
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
May 23, 2024 17:01 ET
|
Cogent Biosciences, Inc.
Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment Encouraging...
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
May 23, 2024 17:01 ET
|
HOOKIPA Pharma Inc.
HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile...
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024 17:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2...
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
Theratechnologies fait une présentation sur le sudocétaxel zendusortide au Congrès 2024 de l’ASCO qui montre des signes d’une efficacité à long terme et un profil d’innocuité gérable chez les patients atteints de tumeurs solides
May 23, 2024 17:00 ET
|
Theratechnologies
L’affiche souligne la stabilisation durable de la maladie après la fin du traitementLes résultats suggèrent un mode d’action multimodal unique qui diffère des autres traitements contre le cancerUne...
MAQUIA CAPITAL ACQUISITION CORPORATION AND IMMERSED INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT
May 23, 2024 17:00 ET
|
Maquia Capital Acquisition Corporation
Miami, Florida and Austin, Texas, May 23, 2024 (GLOBE NEWSWIRE) -- Maquia Capital Acquisition Corporation, a special purpose acquisition company (Nasdaq: MAQC) (“Maquia”), and Immersed Inc., a...